Long-Term Follow-Up Results of Adjuvant Intensity-Modulated Radiotherapy with Concurrent Paclitaxel and Cisplatin in High-Risk Endometrial Cancer Patients
Table 1
Summary of the main randomized controlled trials on adjuvant chemoradiotherapy for high-risk endometrial cancer.
Clinical trial
Number of patients
Treatment methods
Completion rate
LR
DM
5-year OS/DFS
PORTEC 310
330
EBRT+ chemotherapy (consisting of two cycles of cisplatin 50 mg/m2 given during radiotherapy, followed by four cycles of carboplatin AUC 5 and paclitaxel 175 mg/m2)
71%
1.3%
22.4%
81.8%/75.5%
GOG 25811
346
EBRT + chemotherapy (consisting of two cycles of cisplatin 50 mg/m2 given during radiotherapy, followed by four cycles of carboplatin AUC 5 and paclitaxel 175 mg/m2)
75%
13%
27%
76.8%/59%
NSGO/EORTC pooled with Iliade-III9
267
EBRT+ chemotherapy (consisting of four cycles of AP or EP or TAC or TEC or TC)
72%
1%
6.6%
82%/78%
GOG 24912
300
VBT +chemotherapy (consisting of three cycles of carboplatin AUC 6 and paclitaxel 175 mg/m2)
87%
9%
18%
85%/76%
LR: local recurrence; DM: distant metastasis; OS: overall survival; DFS: disease-free survival; EBRT: external-beam radiotherapy; AP: doxorubicin 50 mg/m2 and cisplatin 50 mg/m2; EP: epirubicin 50 mg/m2 and cisplatin 50 mg/m2; TAC: paclitaxel 175 mg/m2 and doxorubicin 40 mg/m2 plus carboplatin AUC 5; TEC: paclitaxel 175 mg/m2 and epirubicin 50 mg/m2 and carboplatin AUC 5; TC: paclitaxel 175 mg/m2 and carboplatin AUC 5-6; VBT: vaginal brachytherapy.
